Century Therapeutics : Corporate Overview May 2024

Corporate Overview

May 2024

Forward-looking statements

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In

some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through

development activities, preclinical studies, and clinical trials; our reliance on

the maintenance on certain key collaborative relationships for the

manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatoryapproval of our product candidates; our ability to successfully integrate operations with Clade Therapeutics, geopolitical issues and inflation on our business andoperations, supply chain and labor force; the performance of thirdparties in connection with the development of our product candidates, including third parties conducting our future clinical

trials as well as third-party suppliers and manufacturers; our ability to

successfully commercialize ourproduct candidates anddevelop sales and

marketing capabilities, if our product candidates are approved; and our ability

to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described morefully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict

all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward- looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

2

Century Therapeutics: Building an industry-leading, next- generation allogeneic iPSC-derived cell therapy platform

LIMITLESS POTENTIAL…

PRECISION DESIGN…

ENDURING IMPACT…

Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturing

Progressing differentiated clinical programs based on Allo-EvasionTM technology in oncology and autoimmune and inflammatory diseases

Well-capitalized into 2026 to enable delivery on key milestones and clinical data

3

Overview of Foundational Platform Technologies

Century's singular focus:

To deliver best-in-classiPSC-derived cell therapies

Century platform enables the incorporation of critical features we believe can only be realized via iPSC-derived cell therapies

	Single cell cloning of engineered
Infinite replicative capacity at the	iPSC allows selection of a fully	Platform capable of fully leveraging
iPSC stage enables potentially unlimited	characterized clone for master cell	multiple advances in synthetic biology
genomic editing via CRISPR HDR	bank, ensuring safety and functional	into a single product
	reproducibility of the final drug product

Cell expansion during multiple stages of	Production from a master cell bank -	Differentiation conditions developed for
differentiation yields large cell harvests,	generating multiple immune effector
derived from a single donor - enables larger
decreasing risk of cell exhaustion,	cells, including NK cells, CD4+ T cells (Th
batch sizes and lower cost of goods than
reducing COGs and providing robust drug	and Treg), CD8+ T cells, monocytes /
donor-derived or autologous
inventory that is potentially infinitely	macrophages
replenishable

5

Century's next-generation allogeneic iPSC technology platform:

Versatility and unprecedented control

Allo-EvasionTM

Homeostasis/ persistence

Modulation of TME

Safety switch

Integration of advances in

synthetic biology

Product design

SINGLE CELL CLONING POST

GENE EDITING AND

iPSC CHARACTERIZATION

Engineered
iPSC MCB	Consistency	iT cell
	Yield
	Fitness: No exhaustion

Manufacturing

DIFFERENTIATION

iNK cell

Rapid Integration of major advances in product functionality and manufacturability

6

Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates

Sequential selection steps

	Multiple gene edits
iPSC	(KO/KI)
bank	iSPC Precision Engineering

Engineered iPSC

Master Cell Bank

(MCB)

Advantages of Century's Platform

Precise CRISPR mediated homology directed repair reduces off-target integration

Stepwise and efficient gene editing avoids risky multiplex modification and structural variants

Quality control through generation of homogenous MCB establishes genomic product integrity

Manufacturing begins at the MCB, confirmed to be free from genetic aberrations

CRISPR-mediated HDR (MAD 7)

7

Potential to drive durable responses with engineering to resist immune rejection

Allo-EvasionTM edits + repeat dosing = potential greater durability

With Allo-EvasionTM engineering

Without Allo-EvasionTM engineering

Next-wave of allogeneic cell therapies must solve for challenge of rejection

8

Advancing our leadership in Allo-EvasionTM technology

Continuous improvement in holistic immune protection designed to overcome major pathways of host vs. graft rejection

Allo-EvasionTM 1.0

Allo-EvasionTM 3.0

Allo-EvasionTM 5.0

Core edits disarm host cells from

eliminating therapy

CD8+

T Cell

Fc

NK cell

1	β2M KO
	(HLA-I)
CD4+	2 CIITA	Pan NK
T Cell	KO	Inhibitory
	(HLA-II)	ligand

Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells

Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells

Knock-in of HLA-E prevents killing by NK cells

Allo-EvasionTM 1.0 edits plus the incorporation of:

Knock-in of HLA-G improves protection against killing by NK cells

Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells

Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells

Pan-NK inhibitory ligand to provide broader protection against killing by NK cells

IgG degrading protease designed to protect against humoral immunity

9

Foundational investments in iPSC manufacturing

Established in-house manufacturing

• Century 53,000 ft2 GMP facility
• Designed to produce multiple immune cell types
• Accelerates learnings and enables faster product iteration
• Two sites (FCDI GMP manufacturing, Century in-house manufacturing) provide optionality and maximizes flexibility

Developing fit-for-purpose products

• Increased process and product consistency
• Scalable platforms and optimized processes to maximize yield, reduce COGs, and meet demand
• Increases in cell fitness, as cells do not undergo excessive expansion cycles which often result in cell exhaustion
• Homogeneity of the manufacturing process produces a product candidate that can be readily characterized

10